Single chain B3 antibody fusion proteins and their uses

Details Single chain B3 antibody fusion proteins and their uses Single chain B3 antibody fusion proteins and their uses

1996-12-03

1999-11-23

Eisenschenk, Frank C.

Organic compounds -- part of the class 532-570 series

Organic compounds

Carbohydrates or derivatives

5303873, 435 691, C07K 1900, C07H 2104

Patent

active

059902965

ABSTRACT:
This invention provides for recombinant single chain antibodies capable of specifically binding to a Lewis.sup.Y -related carbohydrate antigen and fusion proteins comprising these antibodies. More particularly, the invention provides for single chain Fv regions of the monoclonal antibody B3. The invention also provides for a method of improving the binding affinity of antibodies lacking a serine at position 95 of the V.sub.H region that involves mutating position 95 to a serine.

REFERENCES:
patent: 4545985 (1985-10-01), Pastan et al.
patent: 4867962 (1989-09-01), Abrams
patent: 5242813 (1993-09-01), Pastan et al.
patent: 5258498 (1993-11-01), Huston et al.
Colman, Research in Immunology, 1994, 145:33.
Bast et al., J. Clin. Invest. 68:1331-1337 (1981).
Batra et al., J. Biol. Chem. 265:15198-15202 (1990).
Batra et al., Proc. Natl. Acad. Sci. USA 86:8545-8549 (1989).
Better et al., Science, 240:1041-1043 (1988).
Bird et al., Science, 242:423-26 (1988).
Brinkmann et al., Proc. Nat. Acad. Sci. USA 89:3075-3079 (1992).
Brinkmann et al., Biochem. Biophys. Acta. 1198:27-45 (1994).
Chaudhary et al., Nature 339:394-397 (1989).
Chaudhary et al., Proc. Natl. Acad. Sci. USA 87:9491-94 (1990).
Chaudhary et al., Proc. Natl. Acad. Sci. USA 87:1066-1070 (1990).
Hartman et al., E.M.B.O.J. 3:3023-3030 (1984).
Hellstrom et al., Cancer Res. 50:2183-2190 (1990).
Hoess et al., Gene 128:43-49 (1993).
Huston et al., Proc. Natl. Acad. Sci. USA 85:5879-83 (1988).
Jones et al., Nature 321:522-525 (1986).
Kondo et al., J. Biol. Chem. 263:9470-75 (1988).
Morrison et al., Proc. Natl. Acad. Sci. USA 81:6851-6855 (1984).
Pai et al., Proc. Natl. Acad. Sci. USA 88:3358-62 (1991).
Pastan et al., Cancer Res. 51:3781-3787 (1991).
Wawrzynczak et al., Mol. Immunol. 29:213-220 (1992).
Willingham et al., Proc. Natl. Acad. Sci. USA 84:2474-2478 (1987).
Proceedings of the National Academy of Sciences of the USA, vol. 88, No. 19, Oct. 1, 1991 Washington, DC, USA, pp. 8616-8620, U. Brinkmann et al. `B3 (Fv) --PE38KDEL, a single-chain immunotoxin that causes complete regression of a human carcinoma in mice` cited in the application see abstract see figures 1,2.
Bioconjugate Chemistry, vol. 5, No. 4, Jul. 1994 Washington, DC, USA, pp. 321-326, XP 000564453 I. Benhar et al. `Mutations of two lysine residues in the CDR loops of a recombinant immunotoxin that reduce its sensitivity to chemical derivatization.` cited in the application see abstract see figure 1.
Cancer Research, vol. 53, No. 2, Jan. 15, 1993 Philadelphia, PA, USA, pp. 334-339, P. Friedman et al. `BR96 sFv-PE40, a potent single-chain immunotoxin that selectively kills carcinoma cells. ` see abstract see discussion.
The Journal of Immunology, vol. 152, No. 5, Mar. 1, 1994 Baltimore, MD, USA, pp. 2377-2384, C. Siegall et al., `In vitro and in vivo characterization of BR96 sFv-PE40.` see abstract.

Affiliated with

Also associated with

Rating

Single chain B3 antibody fusion proteins and their uses does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Single chain B3 antibody fusion proteins and their uses, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Single chain B3 antibody fusion proteins and their uses will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1223297